Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Post-Marketing Surveillance of Micardis® (Telmisartan) Special Drug Use-results Survey on Long-term Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02242838

Enrollment

6336

Registered

2014-09-17

Start date

2003-09-30

Completion date

Unknown

Last updated

2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The primary objective of this survey is to prospectively investigate safety and efficacy in patients with hypertension treated with telmisartan in proper use in medical practice over a long period

Interventions

DRUGTelmisartan

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with hypertension

Exclusion criteria

Patients with the following conditions * Patients with a history of hypersensitivity of this product * Women in pregnancy (included the possibility of pregnancy) * Patients with severe biliary obstructive disorders or severe hepatic insufficiency

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with adverse drug reactions	up to 1 year	—
Incidence of adverse drug reactions	up to 1 year	classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology
Change in Mean systolic blood pressure (SBP)	up to 1 year	—
Change in Mean diastolic blood pressure (DBP)	up to 1 year	—

Secondary

Measure	Time frame
Overall assessment of efficacy by investigator on 4-point scale	at 3 month, after 1 year
Change in pulse rate	up to 1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026